Medacta received FDA 510(k) clearance to market Anatomic and Reverse Shoulder components for its modular Medacta Shoulder system. U.S. launch will occur in 1Q18.
Anika Therapeutics completed enrollment in its second pivotal Phase III trial evaluating CINGAL® HA/corticosteroid viscosupplement for the treatment of knee osteoarthritis symptoms.